Table 1.
Patient demographics and EEG findings for 21 subjects with anti-NMDAR encephalitis.
| Pediatric (n = 5) | Adult (n = 16) | Total (n = 21) | |
|---|---|---|---|
| Age, median (range) | 13 (11–17) | 28 (18–60) | 26 (11–60) |
| Female, n (%) | 3 (60) | 14 (87.5) | 17 (81) |
| Teratoma present, n (%) | 0 (0) | 10 (62.5) | 10 (47.6) |
| ICU admission, n (%) | 1 (20) | 11 (68.8) | 12 (57.1) |
| Death, n (%) | 0 (0) | 4 (25) | 4 (19) |
| Glasgow Outcome Scale score of 1–3 at 6 months, n (%)* | 1 (25) | 6 (43.9) | 7 (38.9) |
| Glasgow Outcome Scale score of 4–5 at 6 months, n (%)* | 3 (75) | 8 (57.1) | 11 (61.1) |
| All EEGs normal, n (%) | 2 (40) | 0 (0) | 2 (9.5) |
| At least 1 EEG with slowing, n (%) | 3 (60) | 16 (100) | 19 (90.5) |
| At least 1 EEG with extreme delta brush, n (%) | 2 (40) | 7 (43.8) | 9 (42.9) |
*
GOS is not reported for 3 patients as they are fewer than 6 months out from anti-NMDAR encephalitis diagnosis.